Who are the key players in Dysmenorrhea Treatment Market?

Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd and Sanofi are the major companies operating in the Dysmenorrhea Treatment Market. Read More

Which is the fastest growing region in Dysmenorrhea Treatment Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Dysmenorrhea Treatment Market?

In 2024, the North America accounts for the largest market share in Dysmenorrhea Treatment Market. Read More

What years does this Dysmenorrhea Treatment Market cover, and what was the market size in 2023?

In 2023, the Dysmenorrhea Treatment Market size was estimated at USD 4.24 billion. The report covers the Dysmenorrhea Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Dysmenorrhea Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Dysmenorrhea Treatment Market Size

Market Size of Dysmenorrhea Treatment Industry

Study Period	2019 - 2029
Market Size (2024)	USD 4.60 Billion
Market Size (2029)	USD 6.70 Billion
CAGR (2024 - 2029)	7.81 %
Fastest Growing Market	Asia Pacific
Largest Market	North America
Major Players *Disclaimer: Major Players sorted in no particular order

Dysmenorrhea Treatment Market Analysis

The Dysmenorrhea Treatment Market size is estimated at USD 4.60 billion in 2024, and is expected to reach USD 6.70 billion by 2029, growing at a CAGR of 7.81% during the forecast period (2024-2029).

COVID-19 was an unprecedented health concern affecting millions physically and mentally. The pandemic significantly impacted many people's mental health, resulting in loneliness, social isolation, financial strain, anxiety and fear of contracting the virus, and uncertainty for the future. It has been proven that periods of stress and psychological distress can affect a woman's menstrual health. Stressors can activate the hypothalamic-pituitary-gonadal (HPG) axis and alter the neuro-modulatory cascade that drives gonadotropin, releasing hormone (GnRH) regulation, which results in an irregular menstrual cycle. The changes in menstrual cycles lead to higher episodes of dysmenorrhea, significantly impacting the market.

According to a study published in March 2021 by Frontiers in Endocrinology, 46% of women reported a change in their menstrual cycle, with 30% of new dysmenorrhea cases since the pandemic began. Thus, COVID-19 had an impact on the dysmenorrhea treatment market significantly. Even after the pandemic, the market is expected to see a surge over the forecast period with increasing cases of dysmenorrhea and rising research and development.

Dysmenorrhea is commonly known as menstrual cramps, which affects women. The key factors attributed to driving the market growth are the increasing prevalence of dysmenorrhea among adolescent girls and rising cases of menstrual cramps due to genetic disorders. As per the study published in March 2022 by BMC Women's Health, the observed dysmenorrhea in the study; 1107 (92.3%) women had non-pathological dysmenorrhea (primary) while 92 (7.7%) women had pathological dysmenorrhea (secondary) respectively. Moreover, as per a study published in February 2021 by BMJ Open, dysmenorrhea was a common health problem among graduating university students. The prevalence of dysmenorrhea was 317 (51.5%) in Ethiopia. The educational status of the father, chocolate consumption (95%), daily breakfast intake (less than 5 days/week), irregular menstrual cycle, and positive family history of dysmenorrhea, had a statistically significant association with dysmenorrhea. Thus, the increasing burden of dysmenorrhea is expected to boost the growth of the market over the forecast period.

Moreover, increasing research and development for developing innovative drugs is expected to boost the growth of the market. As per a study published in July 2021 by the Journal of Clinical Medicine, various combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and spasmolytics have been developed and tested, demonstrating a huge potential for future research to develop modern, effective combinations and search for new indications for the existing fixed-dose combination drugs for treating dysmenorrhea. Thus, research studies highlighting the potential of existing treatments for menstrual cramps and developing new drugs may drive the market.

However, side effects and complications associated with long-term treatment and lack of awareness about reproductive health in women are expected to restrain the market's growth during the forecast period.

Dysmenorrhea Treatment Industry Segmentation

As per the scope of the report, dysmenorrhea, also known as menstrual cramps, is cramping or throbbing pains in the lower abdomen. Most women experience dysmenorrhea just before and during their menstrual periods. The Dysmenorrhea Treatment Market is Segmented by Treatment Type (Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Hormonal Therapy), Type (Primary Dysmenorrhea and Secondary Dysmenorrhea), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value in USD million for the above segments.

By Treatment Type
		Non-steroidal Anti-inflammatory Drugs (NSAIDs)
		Hormonal Therapy

By Type
		Primary Dysmenorrhea
		Secondary Dysmenorrhea

Geography

North America
	United States
	Canada
	Mexico

Europe
	Germany
	United Kingdom
	France
	Italy
	Spain
	Rest of Europe

Asia-Pacific
	China
	Japan
	India
	Australia
	South Korea
	Rest of Asia-Pacific

Middle-East and Africa
	GCC
	South Africa
	Rest of Middle-East and Africa

South America
	Brazil
	Argentina
	Rest of South America

Need A Different Region Or Segment?

Customize Now

Dysmenorrhea Treatment Market Size Summary

The dysmenorrhea treatment market is poised for significant growth, driven by an increasing prevalence of menstrual cramps among women, particularly adolescents, and the rising incidence of genetic disorders contributing to these conditions. The market is experiencing a surge in demand due to the heightened awareness and prevalence of dysmenorrhea, exacerbated by the psychological stressors associated with the COVID-19 pandemic, which have led to irregular menstrual cycles and increased cases of dysmenorrhea. The market is further bolstered by ongoing research and development efforts aimed at creating innovative treatments, including combinations of non-steroidal anti-inflammatory drugs (NSAIDs) and spasmolytics, which have shown promise in alleviating menstrual pain. Despite the challenges posed by side effects and a lack of awareness about reproductive health, the market is expected to expand as more effective treatments are developed and made available.

North America is anticipated to hold a significant share of the dysmenorrhea treatment market, with the United States playing a pivotal role due to the high incidence of menstrual pain and increased awareness among women. The market is characterized by the presence of major pharmaceutical players such as Novartis AG, Bayer AG, and Pfizer Inc., who are actively involved in launching new products and seeking regulatory approvals to address menstrual pain and related conditions. The approval of treatments like Myfembree for managing heavy menstrual bleeding and the relaunch of OTC medications like Naproxen Sodium Tablets underscore the competitive nature of the market. Additionally, the rising prevalence of endometriosis, a leading cause of secondary dysmenorrhea, is expected to further drive market growth, highlighting the need for effective and accessible treatment options.

Explore More

Dysmenorrhea Treatment Market Size - Table of Contents

1. MARKET DYNAMICS
1. 1.1 Market Overview
2. 1.2 Market Drivers
  1. 1.2.1 Increase In Number of Women with Dysmenorrhea
  2. 1.2.2 Increasing Research and Development for Developing Innovative Drugs
3. 1.3 Market Restraints
  1. 1.3.1 Side Effects and Complications Associated with Long-term Treatment
  2. 1.3.2 Lack of Awareness About Reproductive Health in Women
4. 1.4 Porter's Five Forces Analysis
  1. 1.4.1 Threat of New Entrants
  2. 1.4.2 Bargaining Power of Buyers/Consumers
  3. 1.4.3 Bargaining Power of Suppliers
  4. 1.4.4 Threat of Substitute Products
  5. 1.4.5 Intensity of Competitive Rivalry
2. MARKET SEGMENTATION (Market Size by Value - USD million)
1. 2.1 By Treatment Type
  1. 2.1.1 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  2. 2.1.2 Hormonal Therapy
2. 2.2 By Type
  1. 2.2.1 Primary Dysmenorrhea
  2. 2.2.2 Secondary Dysmenorrhea
3. 2.3 Geography
  1. 2.3.1 North America
    1. 2.3.1.1 United States
    2. 2.3.1.2 Canada
    3. 2.3.1.3 Mexico
  2. 2.3.2 Europe
    1. 2.3.2.1 Germany
    2. 2.3.2.2 United Kingdom
    3. 2.3.2.3 France
    4. 2.3.2.4 Italy
    5. 2.3.2.5 Spain
    6. 2.3.2.6 Rest of Europe
  3. 2.3.3 Asia-Pacific
    1. 2.3.3.1 China
    2. 2.3.3.2 Japan
    3. 2.3.3.3 India
    4. 2.3.3.4 Australia
    5. 2.3.3.5 South Korea
    6. 2.3.3.6 Rest of Asia-Pacific
  4. 2.3.4 Middle-East and Africa
    1. 2.3.4.1 GCC
    2. 2.3.4.2 South Africa
    3. 2.3.4.3 Rest of Middle-East and Africa
  5. 2.3.5 South America
    1. 2.3.5.1 Brazil
    2. 2.3.5.2 Argentina
    3. 2.3.5.3 Rest of South America